An observational study in Limb-girdle Muscular Dystrophy, sponsored by Sarepta Therapeutics, Inc.. Active, not recruiting at 26 sites in 10 countries. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2025-11-06.
Sponsored by Sarepta Therapeutics, Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States — 3 open to participants now, 9 under way, 1 of them phase 3. Muscular Dystrophies, Limb-Girdle · United States.
Among the 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States, this one is the 5th largest by enrollment of the 13 observational ones that give a count, is one of 2 that started in 2021, is one of 13 observational ones, and was the 19th registered.
47 studies on the registry are indexed under Muscular Dystrophies, Limb-Girdle; 10 are open to participants now.
Browse Muscular Dystrophies, Limb-Girdle studies →3 of the 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States are open now. Recruiting first, the newest first:
Virginia Commonwealth University · Sites in United States
Ages 6–50
Cure CMD · Sites in United States
Boston Children's Hospital · Sites in United States
Ages 1 wk–100 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Muscular Dystrophies, Limb-Girdle studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.
This study: 4 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 8 · Phase 3 4
First in 2002; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 205 is above the median of 90 across 22 observational studies indexed under Muscular Dystrophies, Limb-Girdle.
Median enrollment 11 across the 17 interventional studies, 101 across the 13 observational. Of the 18 that completed or were terminated, 5 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 30 have an industry lead sponsor. The 10 most frequent:
Sarepta Therapeutics, Inc. is the lead sponsor of 52 studies on the registry; 8 are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.
Sarepta Therapeutics, Inc. has 9 studies filed under Muscular Dystrophies, Limb-Girdle — fewer than ten, so there is no comparison to draw.
1 of the studies in Muscular Dystrophies, Limb-Girdle with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00390104Boston Children's HospitalMolecular Analysis of Patients With Neuromuscular Disease | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will follow participants who are screened and confirmed with a genetic diagnosis of Limb-girdle muscular dystrophy type 2E (LGMD2E/R4), Limb-girdle muscular dystrophy type 2D (LGMD2D/R3), Limb-girdle muscular dystrophy type 2C (LGMD2C/R5), or Limb-girdle muscular dystrophy type 2A (LGMD2A/R1).
These enrolled participants will be followed to evaluate mobility and pulmonary function for up to 5 years after enrollment for participants with LGMD2C/R5, LGMD2D/R3, and LGMD2E/R4 with a North Star Assessment for Dysferlinopathy (NSAD) ≥ 25 at Baseline, up to 3 years for participants with LGMD2C/R5, LGMD2D/R3, and LGMD2E/R4 with a NSAD \< 25 at Baseline, and up to 3 years for participants with LGMD2A/R1. Additional participant data will be collected from the time the individual began experiencing LGMD symptoms to the present.
LGMD Type 2A, 2C, and 2D cohorts are now closed. Enrollment in the LGMD Type 2E cohort is closed and participants will be followed for up to five years.
The population for this study is ambulatory or non-ambulatory participants ≥ 4 years of age with confirmed genetic diagnosis of LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, or LGMD2A/R1.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with LGMD2E/R4 will be enrolled in this cohort. Enrollment will be capped according to age as follows: 4 to 7 years age range, 8 to 16 years age range, and ≥17 years age range through the course of the study.
Participants with LGMD2D/R3 will be enrolled in this cohort. Enrollment will be capped according to age as follows: 4 to 7 years age range, 8 to 16 years age range, and ≥17 years age range through the course of the study.
Participants with LGMD2C/R5 will be enrolled in this cohort. Enrollment will be capped according to age as follows: 4 to 7 years age range, 8 to 16 years age range, and ≥17 years age range through the course of the study.
Participants with LGMD2A/R1 will be enrolled in this cohort. Enrollment will be capped according to age as follows: 4 to 7 years age range, 8 to 16 years age range, and ≥17 years age range through the course of the study.
NSAD Total Score
Time frame: Baseline up to Month 60
Time to Rise from the Floor
Time frame: Baseline up to Month 60
Time of 10-Meter Walk/Run [10MWR]
Time frame: Baseline up to Month 60
Time to Ascend 4 Steps
Time frame: Baseline up to Month 60
Ankle Range of Motion (ROM)
Time frame: Baseline up to Month 60
Dimension of the Performance of the Upper Limb (PUL)
Time frame: Baseline up to Month 60
Timed Up and Go (TUG)
Time frame: Baseline up to Month 60
Time of 100-Meter Walk/Run (100MWR)
Time frame: Baseline up to Month 60
Pulmonary Function Test: Forced Vital Capacity (FVC)
Time frame: Baseline up to Month 60
Started Apr 2021 (actual). Primary completion is estimated for Sep 2030, 112 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Muscular Dystrophies, Limb-Girdle →